Please wait



Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)


SCHEDULE 13D/A 0001193125-23-271361 0001242110 XXXXXXXX LIVE 1 Common Stock, par value $0.0001 per share 03/10/2025 false 0001799448 01626L204 Aligos Therapeutics, Inc. One Corporate Dr. 2nd Floor South San Francisco CA 94080 Lawrence M. Blatt, Ph.D. (800) 466-6059 One Corporate Dr. 2nd Floor South San Francisco CA 94080 0001242110 N Lawrence M. Blatt, Ph.D. OO N X1 175509 0 175509 0 175509 N 3.2 IN Common Stock, par value $0.0001 per share Aligos Therapeutics, Inc. One Corporate Dr. 2nd Floor South San Francisco CA 94080 This Amendment No. 1 to Schedule 13D ("Amendment No. 1") amends and supplements the Schedule 13D filed with the United States Securities and Exchange Commission (the "SEC") on November 6, 2023 (as amended to date, the "Schedule 13D"), relating to the Voting Common Stock, par value $0.0001 per share (the "Common Stock"), of Aligos Therapeutics, Inc., a Delaware corporation (the "Issuer"). Capitalized terms used herein without definition shall have the meaning set forth in the Schedule 13D. The information contained on the cover page is incorporated by reference into this Item 5. The information presented herein sets forth, as of the date of this Schedule 13D, the aggregate number of shares of Common Stock and percentage of Common Stock beneficially owned by the Reporting Person, as well as the number of shares of Common Stock as to which the Reporting Person has the sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition of, or shared power to dispose or to direct the disposition of, as of the date hereof, based on 5,314,311 shares of Common Stock outstanding as of March 6, 2025, as disclosed in the Issuer's Annual Report on Form 10-K filed with the SEC on March 10, 2025. All amounts reported herein reflect a 1-for-25 reverse stock split of the Issuer's securities effected on August 19, 2024 The Reporting Person's beneficial ownership consists of: (i) 73,902 shares of Common Stock held of record by the Reporting Person; (ii) 4,536 shares of Common Stock held by the Lawrence M. Blatt Living Trust dated 8/27/2014, of which Mr. Blatt is trustee, (iii) 4,904 shares of Common Stock held by the PENSCO Trust Company LLC Custodian FBO Dr. Lawrence Blatt IRA, (iv) 740 shares of Common Stock held by the Zachary David Blatt Irrevocable Trust dated 8/24/2014, (v) 740 shares of Common Stock held by the Zoe Anne Blatt Irrevocable Trust dated 8/24/2014; (vi) 12,206 shares of Common Stock underlying the Common Warrants and (vii) 78,481 shares of Common Stock underlying options that will vest within 60 days of the date hereof. The information contained on the cover page is incorporated by reference to this Item 5. During the past 60 days, the Reporting Person has not effected any transactions with respect to the Common Stock. None. As of the date hereof, the Reporting Person ceased to be the beneficial owner of more than five percent of the outstanding shares of Common Stock. Lawrence M. Blatt, Ph.D. /s/ Lawrence M. Blatt Lawrence M. Blatt, Ph.D. 03/12/2025